Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluticasone furoate in perennial allergic rhinitis
NCT00358475Phase 3
Key facts
- Status
- Completed
- Start
- Jun 2005
- Primary completion
- Oct 2005
- Sponsor
- GSK
- Drugs
- fluticasone
- Conditions
- perennial allergic rhinitis (PAR)
01
Overview
Phase 3, open-label, single-arm trial of fluticasone in perennial allergic rhinitis (PAR), sponsored by GSK. Primary endpoints: Incidence of adverse events at 24 weeks and Changes in laboratory blood test parameters at 24 weeks. Started Jun 2005; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Fluticasone Furoate
03
Who it enrols
Outpatients aged 12 years and older with symptomatic perennial allergic rhinitis.
04
Endpoints
Primary
Incidence of adverse events
Changes in laboratory blood test parameters
Secondary
Change from baseline in nasal symptom score
Beyond the preview
Go deeper on NCT00358475.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00358475.